| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Department of Urology, University of Michigan Urology Center and 2 Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; and 3 Department of Hematology/Oncology and 4 Oncology Research, Centocor, Inc., Malvern, Pennsylvania
Requests for reprints: Robert D. Loberg, University of Michigan, 7312 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0946. Phone: 734-647-3421; Fax: 734-647-9480; E-mail: rloberg{at}umich.edu.
The identification of novel tumor-interactive chemokines and the associated insights into the molecular and cellular basis of tumor-microenvironment interactions have continued to stimulate the development of targeted cancer therapeutics. Recently, we have identified monocyte chemoattractant protein 1 (MCP-1; CCL2) as a prominent regulator of prostate cancer growth and metastasis. Using neutralizing antibodies to human CCL2 (CNTO888) and the mouse homologue CCL2/JE (C1142), we show that treatment with anti-CCL2/JE antibody (2 mg/kg, twice weekly i.p.) attenuated PC-3Luc–mediated overall tumor burden in our in vivo model of prostate cancer metastasis by 96% at 5 weeks postintracardiac injection. Anti-CCL2 inhibition was not as effective as docetaxel (40 mg/kg, every week for 3 weeks) as a single agent, but inhibition of CCL2 in combination with docetaxel significantly reduced overall tumor burden compared with docetaxel alone, and induced tumor regression relative to initial tumor burden. These data suggest an interaction between tumor-derived chemokines and host-derived chemokines acting in cooperation to promote tumor cell survival, proliferation, and metastasis. [Cancer Res 2007;67(19):9417–24]
This article has been cited by other articles:
|
|
 |
|
  G. Solinas, G. Germano, A. Mantovani, and P. Allavena Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation J. Leukoc. Biol., November 1, 2009; 86(5): 1065 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lu and Y. Kang Chemokine (C-C Motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone J. Biol. Chem., October 16, 2009; 284(42): 29087 - 29096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Popivanova, F. I. Kostadinova, K. Furuichi, M. M. Shamekh, T. Kondo, T. Wada, K. Egashira, and N. Mukaida Blockade of a Chemokine, CCL2, Reduces Chronic Colitis-Associated Carcinogenesis in Mice Cancer Res., October 1, 2009; 69(19): 7884 - 7892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hu, L. Sun, C. Guo, Q. Liu, Z. Zhou, L. Peng, J. Pan, L. Yu, J. Lou, Z. Yang, et al. Tumor Cell-Microenvironment Interaction Models Coupled with Clinical Validation Reveal CCL2 and SNCG as Two Predictors of Colorectal Cancer Hepatic Metastasis Clin. Cancer Res., September 1, 2009; 15(17): 5485 - 5493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. GIUNTOLI II, T. J. WEBB, A. ZOSO, O. ROGERS, T. P. DIAZ-MONTES, R. E. BRISTOW, and M. OELKE Ovarian Cancer-associated Ascites Demonstrates Altered Immune Environment: Implications for Antitumor Immunity Anticancer Res, August 1, 2009; 29(8): 2875 - 2884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. MIZUTANI, H. ROCA, Z. VARSOS, and K. J. PIENTA Possible Mechanism of CCL2-induced Akt Activation in Prostate Cancer Cells Anticancer Res, August 1, 2009; 29(8): 3109 - 3113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Carcinogenesis, July 1, 2009; 30(7): 1073 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Izhak, G. Wildbaum, Y. Zohar, R. Anunu, L. Klapper, A. Elkeles, J. Seagal, E. Yefenof, M. Ayalon-Soffer, and N. Karin A Novel Recombinant Fusion Protein Encoding a 20-Amino Acid Residue of the Third Extracellular (E3) Domain of CCR2 Neutralizes the Biological Activity of CCL2 J. Immunol., July 1, 2009; 183(1): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mantovani Chemokines as a Key Component of Cancer-Related Inflammation Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 9 - 13. [Full Text] [PDF]
|
|
|
|
|
|
A. Khatri, Y. Husaini, K. Ow, J. Chapman, and P. J. Russell Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines Clin. Cancer Res., April 1, 2009; 15(7): 2323 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Stathopoulos, I. Psallidas, A. Moustaki, C. Moschos, A. Kollintza, S. Karabela, I. Porfyridis, S. Vassiliou, M. Karatza, Z. Zhou, et al. A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion J Natl Cancer Inst, October 15, 2008; 100(20): 1464 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Roca, Z. Varsos, and K. J. Pienta CCL2 Protects Prostate Cancer PC3 Cells from Autophagic Death via Phosphatidylinositol 3-Kinase/AKT-dependent Survivin Up-regulation J. Biol. Chem., September 5, 2008; 283(36): 25057 - 25073. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
